In November 2025, Biogen received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval of a high dose nusinersen regimen for 5q ...
The new intrathecal formulation means the one-shot gene therapy is now available to all SMA patients, regardless of their age, and could free them from having to take regular, lifelong SMA treatments ...
Biogen Inc (BIIB) stock reached a 52-week high of 177.37 USD, marking a significant milestone for the biotechnology company. This peak reflects an 11.02% increase in its stock price over the past year ...
A high-dose regimen of nusinersen (Spinraza) has been recommended for approval by the CHMP, marking a potential new option ...
TipRanks on MSN
Biogen, Dayra Therapeutics enter research collaboration
Biogen (BIIB) and Dayra Therapeutics announced a research collaboration to discover and develop oral macrocyclic peptides for priority targets in ...
Shares of Biogen (BIIB) are up $7.51, or 4% to $182.81 in pre-market trading after Novo Nordisk (NVO) announced that the 2-year primary analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback